HK Stock Market Move | Henlius (02696) rises by over 8%, broad-spectrum anti-tumor PD-L1 ADC HLX43 Phase II data for esophageal squamous cell carcinoma released for the first time

HENLIUS (02696) rose more than 8%, rising 8.05% as of the time of publication, at 69.8 Hong Kong dollars, with a turnover of 18.64 million Hong Kong dollars. On the news front, on January 9th, at the 2026 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI), HENLIUS announced for the first time the Phase II proof-of-concept (POC) data for its PD-L1 ADC HLX43 in the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC). The data presented this time preliminarily confirmed the therapeutic potential of HLX43 in patients with advanced ESCC who have undergone treatment, demonstrating encouraging efficacy and good safety. HLX43 has been observed to exhibit sustained and consistent efficacy and safety trends in several solid tumor indications such as non-small cell lung cancer, cervical cancer, esophageal squamous cell carcinoma, and thymoma. Its broad-spectrum anti-tumor potential is gradually being validated through clinical practice, laying an important foundation for expanding to more indications in the future. It is worth noting that the 44th annual J.P. Morgan Healthcare Conference (JPM 2026) will be held from January 12-15 in San Francisco, USA. As one of the most influential annual events in the global healthcare field, the JPM conference is considered an important window for observing medical innovation and industry trends in the global capital markets. Dr. Zhu Jun, Executive Director and CEO of HENLIUS, will deliver a keynote speech at the conference on January 15 local time, sharing the company's latest progress and future plans with international investors and industry professionals regarding the development path of the company's globalization 2.0 stage, innovative pipeline layout, and medium- to long-term strategic planning.